Genie Energy to Report First Quarter 2026 Results 

Annual meeting of Genie stockholders will be held June 10, 2026

NEWARK, NJ, May 08, 2026 (GLOBE NEWSWIRE) — Genie Energy Ltd., (NYSE: GNE), a leading retail energy and renewable energy solutions provider, will announce financial and operational results for the first quarter 2026 on Thursday, May 14, 2026.

Genie Energy will announce its results through an earnings release issued over a wire service and posted in the “Investors” section of the Genie Energy website (https://genie.com/investors/quarterly-earnings/) at 7:30 AM Eastern. The release also will be filed in a current report (Form 8-K) with the SEC.

At 8:30 AM Eastern, Genie Energy’s management will host a conference call to discuss financial and operational results, business outlook, and strategy. The call will begin with management’s remarks followed by Q&A with investors.

To participate in the conference call, dial 1-888-506-0062 (toll-free from the US) or 1-973-528-0011 (international) and provide the following participant access code: 359213.

Approximately three hours after the call, a call replay will be accessible by dialing 1-877-481-4010 (toll-free from the US) or 1-919-882-2331 (international) and providing the replay passcode: 53980. The replay will remain available through Thursday, May 28, 2026. In addition, a recording of the call will be available for playback through the Genie Energy website

The date of Genie Energy’s Annual Meeting of Stockholders has been changed from June 3, 2026 to June 10, 2026 at 2:30 p.m. at Genie Energy’s headquarters (520 Broad Street, 4th Floor, Newark, New Jersey 07102).

In this press release, all statements that are not purely about historical facts, including, but not limited to, those in which we use the words “believe,” “anticipate,” “expect,” “plan,” “intend,” “estimate, “target” and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors, including, but not limited to, those described in our most recent report on SEC Form 10-K (under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”), which may be revised or supplemented in subsequent reports on SEC Forms 10-Q and 8-K. We are under no obligation, and expressly disclaim any obligation, to update the forward-looking statements in this press release, whether as a result of new information, future events or otherwise. 

About Genie Energy Ltd.: 

Genie Energy Ltd., (NYSE: GNE) is a leading retail energy and renewable energy solutions provider. The Genie Retail Energy division (GRE) supplies electricity, including electricity from renewable resources, and natural gas to residential and small business customers in the United States. The Genie Renewables division (GREW) holds Genie’s energy brokerage and advisory business, a portfolio of solar generation assets, and early-stage growth initiatives. For more information, visit Genie.com.

Contact: 

Genie Energy Investor Relations
Bill Ulrey
E-mail: [email protected] 

# # # 



Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.

On February 27, 2026, Fulgent reported its fourth quarter and full year 2025 financial results. The Company disclosed that full year 2025 revenue was approximately $322.7 million, which fell slightly short of the updated guidance previously provided. Fulgent also reported that fourth quarter revenue declined sequentially.

If you suffered a loss in the Company securities, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact our attorneys Andrea Farah at (914) 733-7256 or via email to [email protected] or Vincent R. Cappucci Jr. at (914) 733-7278 or via email at [email protected].

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

Contact

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email: [email protected] 



Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws.

On March 24, 2026, Culper Research, an investigative research firm, published a report titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported.” The report revealed, among other things, that in 2025 ADMA Biologics induced one of its distributors to “stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations.” This allegedly allowed ADMA Biologics to book revenue and “report[] growth that was never there.” According to Culper Research, had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.

If you suffered a loss of more than $50,000 in ADMA Biologics securities, and wish to participate, or learn more about your eligibility, click here, or contact our attorneys Andrea Farah ([email protected]) at (914)733-7256 or Vincent R. Cappucci Jr. ([email protected]) at (914)733-7278.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

Contact

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email:  [email protected] 

SOURCE: Lowey Dannenberg



Hub Group (NASDAQ: HUBG) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a top complex litigation law firm, is investigating Hub Group Inc. (NASDAQ: HUBG) (“Hub Group” or the “Company”) for potential violations of the federal securities laws.

On February 5, 2026, Hub Group announced that it would restate its financial statements for the first, second, and third quarters of 2025 due to an error that resulted in the understatement of purchased transportation costs and accounts payable. The Company disclosed that the total reduction to accounts payable and purchased transportation costs related to the identified error was $77 million for the nine months ended September 30, 2025. The Company delayed its full earnings release and stated that it is continuing to assess the potential impact on its financial statements for 2023 and 2024, indicating the scope of the accounting errors may extend beyond 2025.

“Our investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,” said attorney Andrea Farah, Lowey Dannenberg, P.C. partner and head of the firm’s securities practice.

If you suffered a loss of more than $50,000 in Hub Group securities, and wish to participate, or learn more about your eligibility, click here, or contact our attorneys Andrea Farah ([email protected]) at (914)733-7256 or Vincent R. Cappucci Jr. ([email protected]) at (914)733-7278.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

Contact

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email:  [email protected] 

SOURCE: Lowey Dannenberg



NRSInsights’ April 2026 Retail Same-Store Sales Report

April same-store sales increased 3.9% year-over-year 

The average price paid for the top 500 items in April increased 2.2% year-over-year

NEWARK, N.J., May 08, 2026 (GLOBE NEWSWIRE) —  NRSInsights, a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative retail same-store sales results for April 2026.

As of April 30, 2026, the NRS retail network comprised approximately 39,300 active terminals nationwide, scanning purchases at approximately 34,100 independent retailers, including convenience stores, bodegas, liquor stores, grocers, and tobacco and sundries sellers, predominantly serving urban consumers.


April Highlights

(Same-store sales, unit sales, transactions, and average price data refer to April 2026 and are compared to April 2025 unless otherwise noted. All comparisons are provided on a “per calendar day” basis to remove from consideration variability in the number of days per month or three-month period.)

  • SALES
    • Same-store sales increased 3.9% year-over-year. In the previous month (March 2026), same-store sales increased 2.9% year-over-year.
    • Same-store sales increased 1.7% compared to the previous month (March 2026). Same-store sales in March 2026 increased 4.3% compared to the previous month (February 2026).
    • For the three months ended April 30, 2026, same-store sales increased 3.2% compared to the corresponding three months a year ago.
  • UNITS SOLD
    • Units sold increased 0.5% year-over-year. In the previous month (March 2026), units sold decreased 1.2% year-over-year.
    • Units sold increased 1.3% compared to the previous month (March 2026). Units sold in March 2026 increased 4.0% compared to the previous month (February 2026).
  • BASKETS (TRANSACTIONS) PER STORE
    • Baskets decreased 0.3% year-over-year. In the previous month (March 2026), baskets decreased 0.4% year-over-year.
    • Baskets increased 2.9% compared to the previous month (March 2026). Baskets in March 2026 increased 6.5% compared to the previous month (February 2026).
  • AVERAGE PRICES
    • A dollar-weighted average of prices for the top 500 items purchased in April 2026 increased 2.2% year-over-year, more than the 1.4% year-over-year increase in March 2026.


Commentary from Brandon Thurber


(VP, Data Sales & Client Success at NRS)

“Same-store sales accelerated in April, increasing 3.9% year-over-year compared to the 2.9% year-over-year growth recorded in March. The growth was powered by an increase in dollar sales per basket, which more than compensated for a slight decrease in transactions, continuing a long-term trend of increasing average per-visit spend.

“Turning to category performance, prepared cocktails and espresso experienced the strongest growth, and coconut water, sparkling water, and smokeless tobacco each posted strong double-digit gains. Rolling papers, frozen novelty, and wine-based cocktails also continued their steady climbs.

“Regionally, Raleigh Durham led the pack with a double-digit year-over-year sales increase while Los Angeles, Washington DC and Miami / Ft. Lauderdale all registered slight decreases.

“Our measure of inflation, reflecting the relative prices of the 500 top-selling products within our network, remained subdued at 2.2%.”


NRSInsights Reports

The NRSInsights monthly Retail Same-Store Sales Reports are intended to provide timely topline data reflective of sales at NRS’ network of independent, predominantly urban, retail stores.  

Same-store data comparisons of April 2026 with April 2025 are derived from approximately 232 million transactions processed through the approximately 25,300 stores on the NRS network that scanned transactions in both months. Same-store data comparisons of April 2026 with March 2026 are derived from approximately 283 million transactions processed through approximately 33,000 stores.

Same-store data comparisons for the three months ended April 2026 with the year-ago three months are derived from approximately 643 million transactions processed through stores that scanned transactions in both three-month periods.


NRS POS Platform

The NRS platform predominantly serves small-format, independent, retail stores nationwide including convenience stores, bodegas, liquor stores, grocers, and tobacco and sundries sellers. These independent retailers operate in all 50 states and the District of Colombia, including 206 of the 210 designated market areas (DMAs) in the United States, and in Canada.   During April 2026, NRS’ POS terminals processed $2.2 billion in sales (+13% year-over-year) across 145 million transactions.


About National Retail Solutions (NRS):

National Retail Solutions operates a leading point-of-sale (POS) terminal-based platform and digital payment processing service for independent retailers nationwide. Retailers utilize NRS offerings to process transactions, effectively manage their businesses, and integrate with leading online order and delivery platforms. Consumer packaged goods (CPG) suppliers, brokers, analytics firms, and advertisers access the terminal’s digital display network to reach these retailers’ predominantly urban, multi-cultural shopper base, and to harness transaction data-based learnings to identify growth opportunities and measure both execution and returns on marketing investment. NRS is a subsidiary of IDT Corporation (NYSE: IDT).

All statements above that are not purely about historical facts, including, but not limited to, those in which we use the words “believe,” “anticipate,” “expect,” “plan,” “intend,” “estimate,” “target” and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors. Our filings with the SEC provide detailed information on such statements and risks, and should be consulted along with this release. To the extent permitted under applicable law, IDT assumes no obligation to update any forward-looking statements.


NRSInsights Contact:


Brandon Thurber
VP, Data Sales & Client Success at NRS
National Retail Solutions
[email protected]


IDT Corporation Contact:

Bill Ulrey
[email protected]

# # #



Merit Medical to Participate in the Bank of America Healthcare Conference

SOUTH JORDAN, Utah, May 08, 2026 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that Merit management will participate in the Bank of America 2026 Health Care Conference, to be held in Las Vegas, Nevada, May 12-14, 2026.

The management team will participate in a fireside chat session on Tuesday, May 12th at 3:00 pm Pacific Time / 6:00 pm Eastern Time.

A live audio webcast of the fireside chat will be accessible under the “Events” section of the Company’s investor relations website at Investor Events and Presentations – Merit Medical. A replay of the fireside chat will be available on this same website for approximately 90 days.

ABOUT MERIT MEDICAL

Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.

CONTACTS 

PR/Media Inquiries 
Sarah Comstock

Merit Medical 
+1-801-432-2864 | [email protected] 

Investor Inquiries 
Mike Piccinino, CFA, IRC 
ICR Healthcare 
+1-443-213-0509 | [email protected]



Sono Group N.V. Completes Exit from Legacy Solar Operations

Transfer of Sono Motors to Its Management Team Marks Full Completion of the Strategic Transition Announced in March 2026; Sono Group Currently Operates as a Focused Digital Asset Treasury Company

Munich, Germany, May 08, 2026 (GLOBE NEWSWIRE) — Sono Group N.V. (Nasdaq: SSM) (hereafter referred to as “Sono” or the “Company”) today announced the completion of a decisive milestone in its ongoing strategic transformation: the formal transfer of its now former subsidiary Sono Motors GmbH (“Sono Motors”) to companies controlled by Sono Motors’ own management team. The transaction closed and took legal effect on May 4, 2026, bringing to a close the solar exit the Company announced in March. Sono Group holds no further equity interest in Sono Motors and carries no ongoing operational obligations to the business.

With this transaction complete, the Company turns fully to the Treasury Strategy: acquiring Bitcoin and generating yield through a covered-call approach under its institutional ISDA framework. The proceeds of the Company’s March 2026 financing were deployed into Bitcoin acquisition immediately upon receipt, capital that would otherwise have been partially absorbed by legacy solar operations. With the exit complete, there is no longer a competing claim on that capital.

The legacy solar business was transferred to Sono Motors’ two managing directors, Denis Azhar and Jan Schiermeister, who acquired it directly, together with the technology and the team they led. The brand’s solar heritage and the people behind it remain in capable hands. Sono Group retains an irrevocable, royalty-free license to continue operating under the Sono name for its stock exchange listing and securities trading.

Sono Group currently operates as a digital asset treasury company and will continue to evaluate opportunities to build long-term shareholder value as its strategy develops.

“I want to thank the Sono Motors team: what Denis, Jan and their colleagues built earned real industry recognition, and I’m glad it passes to people who believe in it. For Sono Group, the transformation we announced in March is now complete. We are focused on execution and on delivering results for our shareholders,” said Kevin McGurn, Managing Director and CEO of Sono Group N.V.

Full details of the transaction, including the Share Purchase and Transfer Agreement, are set forth in the Company’s Amendment No. 1 on Form 8-K/A filed with the U.S. Securities and Exchange Commission on May 6, 2026, available at www.sec.gov and on the Company’s investor relations website at ir.sonomotors.com.

ABOUT SONO GROUP N.V.

Sono Group N.V. (Nasdaq: SSM) is a Netherlands-incorporated company listed on the Nasdaq Capital Market, currently operating as a digital asset treasury company. The Company’s Treasury Strategy is centered on the acquisition of Bitcoin and the generation of structured yield through an institutional covered-call approach under an ISDA Master Agreement framework. For more information about Sono Group N.V. visit sonogroupnv.com. Follow us on social media: LinkedIn, Facebook, BlueSky, Truth Social, and X.

FORWARD-LOOKING STATEMENTS

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding the consummation of transactions as part of the Treasury Strategy, including their timing and the expected cash flow and the use of proceeds therefrom; the receipt of any required shareholder approvals; the projected operational and financial performance of the Company and its subsidiaries, including the Company following implementation of the Treasury Strategy; the Company’s product offerings and developments and business plans; and the Company’s expectations, hopes, beliefs, intentions, plans, prospects or strategies regarding the future revenue and the business plans of the Company’s management team, including the pursuit of the Treasury Strategy. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release  are based on certain assumptions and analyses made by the management of the Company considering their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the consummation and timing of any transactions as part of the Treasury Strategy, and the cash flow to the Company therefrom; the occurrence of any uncured event of default or any event, change or other circumstance that could give rise to the termination of the Company’s ISDA Master Agreement relating to the Treasury Strategy; the outcome of any legal proceedings that may be instituted against the Company; risks associated with the Treasury Strategy replacing the former plans and operations of the Company including the legacy solar operations; potential difficulties in employee retention as a result of the Treasury Strategy; whether the Company will be able to maintain compliance with the continued listing standards of The Nasdaq Stock Market LLC or comply with the initial listing standards of another national securities exchange; the ability of the Company to service or otherwise pay its debt obligations; market acceptance of the Company’s product offerings; that the Company will have sufficient capital to operate as anticipated; the demand for the Company’s products; and global supply chains and legislative, regulatory and economic developments in general. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as may be required under applicable securities laws.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

In connection with the solicitation of the ratification by the Company’s shareholders of the engagement by the Company in the Treasury Strategy, the Company intends to file with the Securities and Exchange Commission (the “SEC”) a proxy statement on Schedule 14A (the “Proxy Statement”) relating to an extraordinary general meeting of the Company’s shareholders to be held for the purpose of ratifying the Company’s engagement in the Treasury Strategy (the “Special Meeting”). This press release  is not a substitute for the Proxy Statement or any other document that the Company may file with the SEC or send to the Company’s shareholders in connection with the Special Meeting. This press release  does not contain all of the information that should be considered in respect of the matters to be noticed for the Special Meeting in the Proxy Statement, and additional information will be set forth in the Proxy Statement when it becomes available. Shareholders of the Company are urged to read all relevant documents filed with the SEC, including the Proxy Statement, as well as any amendments or supplements to these documents, carefully when they become available. Promptly after filing its definitive Proxy Statement with the SEC, the Company will mail the definitive Proxy Statement and a proxy card to each shareholder of the Company entitled to vote at the Special Meeting as of a record date to be established for voting at the Special Meeting.
Shareholders may also obtain a copy of the Proxy Statement, as well as other documents filed by the Company with the SEC without charge, at the SEC’s website located at www.sec.gov. In addition, shareholders may obtain a free copy of the Company’s filings with the SEC from the Company’s website at https://ir.sonomotors.com/.

PARTICIPANTS IN THE SOLICITATION

The Company and its directors, executive officers, employees and other persons may be deemed to be participants in the solicitation of proxies from the Company’s shareholders in connection with the Special Meeting under SEC rules. Shareholders may obtain more detailed information regarding the names, affiliations and interests of the Company’s executive officers and directors in the solicitation by reading the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC on April 1, 2026 and the Proxy Statement when it becomes available.

NO SOLICITATION

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the matters to be noticed in the definitive Proxy Statement when it becomes available.



Press:
[email protected] | ir.sonomotors.com/news-events
Investors:
[email protected] | ir.sonomotors.com
LinkedIn:
https://www.linkedin.com/company/sonogroupnv

Flag Ship Acquisition Corporation Enters into Letter of Intent with Bluechip & Co. Holdings

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Flag Ship Acquisition Corporation (the “Company”) (NASDAQ: FSHP), a special purpose acquisition company, today announced that it has entered into a binding letter of intent (“LOI”) with Bluechip & Co. Holdings (“Bluechip”) in connection with a proposed business combination. The letter of intent includes binding provisions regarding exclusivity and other related transaction provisions governing the parties’ negotiations during the proposed transaction process. The proposed transaction remains subject to due diligence, negotiation and execution of definitive agreements, satisfaction of customary closing conditions, and approval by the boards and shareholders of the relevant parties.

The proposed transaction contemplates that the Company or a successor public company will acquire 100% of the equity interests of Bluechip through a share exchange, merger, consolidation or otherwise. The final structure for the transaction will be evaluated and mutually agreed by the parties. Based on preliminary discussions, Bluechip’s implied equity valuation is expected to range between $300 million and $400 million. The LOI provides for an exclusive negotiation period, during which the Company will conduct comprehensive due diligence on Bluechip and the parties will negotiate the terms of a definitive merger agreement. The parties have agreed to a ninety (90) day period of mutual exclusivity, which may be extended under certain conditions as specified in the LOI.

Bluechip operates a cross-border financial services platform primarily focused on insurance-related customer acquisition, financial education, and referral services, complemented by advisory services related to U.S. capital markets transactions. Its platform is designed to connect individual clients with international insurance solutions while providing corporate clients and investors with access to U.S. capital markets opportunities across multiple jurisdictions. Bluechip’s operations are currently organized into two primary business lines: (i) cross-border insurance-related services, which represent its principal source of revenue, and (ii) U.S. capital markets advisory services.

Matthew Chen, Chairman of Flag Ship Acquisition Corporation, commented: “We are pleased to enter into this binding letter of intent with Bluechip, a platform that we believe is well-positioned in the growing cross-border financial services market. We look forward to working closely with Bluechip’s management team as we advance our due diligence and negotiate a definitive agreement.”

Ming Zhang, Chairman and Founder of Bluechip & Co. Holdings, added: “This transaction represents an exciting opportunity to accelerate our growth and expand our access to global capital markets. We believe that partnering with Flag Ship will enhance our ability to serve clients across jurisdictions and strengthen our position in both insurance-related services and capital markets advisory services.”

About Flag Ship Acquisition Corporation

Flag Ship is a blank check company, also commonly referred to as a Special Purpose Acquisition Company, or SPAC, formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities. Flag Ship’s efforts to identify a target business have not been limited to a particular industry or geographic region. Flag Ship is sponsored by Whale Management Corporation, a BVI business company with limited liability.

About Bluechip & Co. Holdings

Bluechip is an exempt company incorporated in Cayman Islands. Through its subsidiaries in Hong Kong, it operates a cross-border financial services platform primarily focused on insurance-related customer acquisition, financial education, and referral services, complemented by advisory services related to U.S. capital markets transactions.

Definitive Documentation

The parties will announce additional details regarding the proposed transaction if and when a definitive agreement is executed. No assurances can be provided as to the entry into or timing of any definitive agreement or the consummation of any transaction. Any transaction would be subject to the completion of satisfactory due diligence, the negotiation of a definitive agreement and related ancillary agreements providing for the proposed acquisition, satisfaction of the conditions negotiated therein, board and shareholder approvals, regulatory approvals and other customary conditions.

Additional Information and Where to Find It

If a definitive agreement is entered into in connection with the proposed transaction, the Company or a newly formed holding company will prepare and file a proxy statement/prospectus with the U.S. Securities and Exchange Commission (the “SEC”). The Company urges investors and securityholders to read the proxy statement/prospectus and other documents filed with the SEC when they become available, as they will contain important information regarding the proposed acquisition. The proxy statement/prospectus will be distributed to the Company’s public shareholders in connection with the Company’s solicitation of proxies for the vote by its shareholders with respect to the proposed transaction and other matters as will described therein. All SEC filings will be available free of charge at www.sec.gov.

No Offer or Solicitation

This release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of any business combination. This release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

The Company, Bluechip, and their respective directors and executive officers may be deemed participants under SEC rules in the solicitation of proxies in connection with the proposed transaction. Information regarding the Company’s directors and executive officers is available in the Company’s SEC filings. Additional details regarding the interests of persons involved in the proposed acquisition will be included in the proxy statement/prospectus when it becomes available.

Forward Looking Statements

This press release includes certain “forward-looking” statements, as that term is defined under the federal securities laws, regarding the Company and Bluechip. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The expectations, estimates, and projections of the businesses of the Company and Bluechip may differ from their actual results, and accordingly, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements generally are identified by the words or phrases such as “aspire,” “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “will be,” “will continue,” “will likely result,” “could,” “should,” “believe(s),” “predicts,” “potential,” “continue,” “future,” “opportunity,” seek,” “intend,” “strategy,” or the negative version of those words or phrases or similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to the execution and delivery of a definitive agreement with respect to the proposed transaction, future performance and anticipated financial impacts of the proposed transaction, the satisfaction of the closing conditions to, and the timing of, the completion of the proposed transaction. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Many of these factors are outside of the control of the Company and Bluechip and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the negotiations and any subsequent definitive agreements with respect to the proposed transaction, and the possibility that the terms and conditions set forth in any definitive agreements with respect to the proposed transaction may differ materially from the terms and conditions set forth in the letter of intent; (2) the outcome of any legal proceedings that may be instituted against the parties following the announcement of the proposed transaction and any definitive agreements with respect thereto; (3) the inability to complete the proposed transaction, including due to failure to obtain approval of the shareholders of the Company or Bluechip or other conditions to closing; (4) the inability to obtain or maintain the listing of the Company’s securities on the Nasdaq Stock Market LLC, or another national securities exchange following the proposed transaction; (5) the risk that the proposed transaction disrupts current plans and operations as a result of the announcement and consummation of the proposed transaction; (6) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, competition, the ability of Bluechip to grow and manage growth profitably and retain its key employees; (7) costs related to the proposed transaction; (8) changes in applicable laws or regulations; (9) risks related to Bluechip’s business, competition within the industry, potential delays or cost overruns in capital expenditures, compliance with regulatory requirements, economic and market conditions, and political or geopolitical developments; and (10) other risks and uncertainties included in documents filed or to be filed with the SEC by the Company and Bluechip. The foregoing list of factors is not exclusive.

You should not place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date hereof, and, except as required by law, the Company assumes no obligation and does not intend to update any forward-looking statement to reflect events or circumstances after the date hereof. Past performance by the Company and Bluechip is not a guarantee of future performance. Therefore, you should not place undue reliance on the historical record of the performance of the Company and Bluechip as indicative of future performance of an investment or the returns that the Company or Bluechip will, or are likely to, generate going forward.

For further information, please contact:

Matthew Chen | Chief Executive Officer
Phone: (212) 884-2667
Email: [email protected]



ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology

Patent Expands Company’s Proprietary Surface Acoustic Wave Platform into Advanced Therapeutic Delivery Applications

TYLER, Texas, May 08, 2026 (GLOBE NEWSWIRE) — ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/025,969, covering a novel drug delivery system utilizing the Company’s proprietary surface acoustic wave (SAW) technology to enhance transdermal delivery of cannabinoid-based therapeutics.

The allowed claims provide broad intellectual property protection across multiple components of the combined SAW ultrasound and cannabinoid transdermal delivery system, including transdermal patch configurations, portable SAW-generating platforms, and methods shown to produce synergistic enhancement in cannabinoid absorption through the skin compared to administration via the transdermal patch alone.

Cannabinoid-based therapeutics continue to attract growing scientific, pharmaceutical, and commercial interest globally, particularly in pain management, neurology, inflammation, and chronic disease applications. ENvue Medical believes its ultrasound-based delivery platform may provide future opportunities to improve therapeutic administration and enable strategic collaborations across multiple treatment categories.

“This Notice of Allowance validates a meaningful expansion of our SAW platform into an entirely new therapeutic category,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “We believe that the USPTO’s recognition of the synergistic effect between our ultrasound technology and cannabinoid transdermal delivery, and its determination that this combination was non-obvious, reflects the depth and breadth of our intellectual property portfolio. We believe this positions ENvue favorably as interest in cannabinoid-based therapeutics continues to grow, and we look forward to exploring the strategic opportunities this patent creates for the Company.”

The Company believes this patent allowance further reinforces the value and versatility of its proprietary SAW technology platform and highlights the potential for future applications beyond its currently marketed products.

About ENvue Medical, Inc.

ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:

  • ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
  • ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
  • Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Investor Contact:

KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
[email protected]

Media Contact:

KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
[email protected]



Celsius Holdings to Participate in Upcoming Investor Conferences

Celsius Holdings to Participate in Upcoming Investor Conferences

BOCA RATON, Fla.–(BUSINESS WIRE)–Celsius Holdings, Inc. (Nasdaq: CELH) (“the Company”) today announced it will participate in the following investor conferences:

Goldman Sachs Global Staples Forum

Date: May 12, 2026

Fireside chat webcast: May 12, approximately 8 a.m. ET

Deutsche Bank Global Consumer Conference

Date: June 2, 2026

Fireside chat webcast: June 2, approximately 5:15 p.m. CEST / 11:15 a.m. ET

Jefferies Consumer Conference

Date: June 16-17, 2026

Live webcasts (where applicable) will be available in the Events & Presentations section of the Company’s investor relations website at: https://ir.celsiusholdingsinc.com/events-and-presentations/. As disclosed in our Annual Report on Form 10-K filed with the Securities & Exchange Commission (the “SEC”) on April 14, 2026, we use our website and webcasts as means of disclosing material information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Attendees are reminded to join the webcasts before the planned start time to ensure a good connection and to allow for time to complete the free registration. We intend to make replays of the webcast noted above available on our website for at least 30 days after the original conference date.

About Celsius Holdings, Inc.

Celsius Holdings, Inc. (Nasdaq: CELH) is a functional beverage company and the owner of energy drink brand CELSIUS®, health and wellness brand Alani Nu® and Rockstar Energy®. Born in fitness and pioneering the rapidly growing, better-for-you, functional beverage category, the company creates and markets leading functional beverage products. For more information, please visit www.celsiusholdingsinc.com.

Investor Relations Contact:

Paul Wiseman

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Food/Beverage Retail

MEDIA:

Logo
Logo